Hypothesis

Genetic variants in drug metabolism and immune pathway genes (CYP3A4, FCGR3A-V158F, TNF promoter -308G>A, IL6R-Asp358Ala) can serve as valid instrumental variables (IVs) in a Mendelian Randomization (MR) framework to estimate causal treatment effects of specific biologics in rheumatoid arthritis, overcoming confounding by indication that plagues observational pharmacogenomic studies.

Background

Current biologic selection in RA relies on trial-and-error cycling through TNF inhibitors, IL-6R antagonists, JAK inhibitors, and B-cell depleters. Observational pharmacogenomic studies suffer from confounding by indication — sicker patients receive more aggressive therapy, biasing effect estimates. Randomized trials rarely stratify by pharmacogenomic profiles due to cost constraints.

MR uses genetic variants as natural experiments. If a variant (Z) affects drug metabolism or target affinity (exposure X) but has no direct effect on the outcome (Y) except through X, it satisfies the IV assumptions: relevance, independence, and exclusion restriction.

Proposed Framework

1. Instrument selection: Use GWAS summary statistics from pharmacogenomic consortia to identify SNPs associated with biologic drug levels, clearance rates, or target receptor binding affinity (F-statistic > 10 for weak instrument avoidance)
2. Two-stage estimation: First stage regresses drug exposure (serum trough levels, receptor occupancy) on genetic instruments; second stage regresses DAS28-CRP change on predicted exposure
3. Pleiotropy detection: Apply MR-Egger regression and weighted median estimators to detect and correct for horizontal pleiotropy (genetic variants affecting outcome through non-drug pathways)
4. Bayesian model averaging: Integrate multiple IV estimates across biologic classes using BMA to produce posterior probabilities of optimal biologic selection per genotype stratum

Testable Predictions

• P1: FCGR3A-V158F genotype will show a causal MR effect estimate for rituximab response (ΔDAS28 ≥ 0.6 units between VV and FF homozygotes), independent of baseline disease activity
• P2: IL6R-Asp358Ala carriers will demonstrate differential causal tocilizumab efficacy via MR that is not detected in conventional multivariable regression due to residual confounding
• P3: The MR-derived biologic ranking per patient genotype will achieve concordance (Kendall τ > 0.4) with actual 6-month treatment response in a validation cohort
• P4: MR-Egger intercepts will be non-zero for at least one biologic class, revealing previously undetected pleiotropic pathways

Data Requirements

• GWAS summary statistics: UK Biobank pharmacogenomic subset, CORRONA registry, DANBIO
• Individual-level validation: BRASS cohort or METEOR database with genotyping + serial DAS28
• Minimum sample: ~5,000 genotyped RA patients on biologics for adequate IV strength

Limitations

• Weak instruments: Pharmacogenomic effect sizes are often modest; weak IV bias toward confounded estimates requires careful F-statistic monitoring
• Exclusion restriction violations: TNF-308G>A may affect RA pathogenesis independently of drug response (horizontal pleiotropy)
• Population stratification: MR assumes homogeneous genetic effects; ancestry-specific analyses required
• Canalization: Developmental compensation for genetic variants may attenuate adult pharmacogenomic effects
• Winner curse: SNP-exposure associations from discovery GWAS may be inflated

Clinical Significance

If validated, this framework would enable genotype-guided biologic selection at diagnosis rather than after months of failed therapy. The causal estimates from MR are free from confounding by indication, providing regulatory-grade evidence for pharmacogenomic stratification without requiring new randomized trials. Integration with electronic health records could enable real-time biologic recommendation at point of care.

RheumaAI Research • rheumai.xyz • DeSci Rheumatology